Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan
- 21 February 2012
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 18 (2) , 306-313
Abstract
There are few reports of long-term treatment with docetaxel in castration-resistant prostate cancer (CRPC) because of the limit of a maximum of ten cycles of treatment in TAX327 showing a survival benefit. Therefore, this study, ARD6563, was conducted to evaluate the safety of more than ten cycles of docetaxel in metastatic CRPC.Keywords
This publication has 16 references indexed in Scilit:
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Phase II study of docetaxel re‐treatment in docetaxel‐pretreated castration‐resistant prostate cancerBJU International, 2011
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patientsInternational Journal of Clinical Oncology, 2009
- Docetaxel Plus Prednisolone for the Treatment of Metastatic Hormone-refractory Prostate Cancer: A Multicenter Phase II Trial in JapanJapanese Journal of Clinical Oncology, 2008
- Intermittent chemotherapy in patients with metastatic androgen‐independent prostate cancerCancer, 2007
- Chemotherapy for the treatment of hormone-refractory prostate cancerInternational Journal Of Clinical Practice, 2007
- Explaining Interindividual Variability of Docetaxel Pharmacokinetics and Pharmacodynamics in Asians Through Phenotyping and Genotyping StrategiesJournal of Clinical Oncology, 2002
- Clinical Pharmacokinetics of DocetaxelClinical Pharmacokinetics, 1999
- Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of TaxolJNCI: Journal of the National Cancer Institute, 1991